
U.S. stocks were higher, with the Nasdaq Composite gaining more than 100 points on Thursday.
Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) rose sharply during Thursday's session after the company reported clinical results from its Phase 1 healthy volunteer study of MZE782. The company secured $150 million in oversubscribed private placement.